Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke - PubMed (original) (raw)
Review
doi: 10.1038/sj.jcbfm.9600516. Epub 2007 Jun 20.
Margaret M Zaleska, Michael Krams, Xinkang Wang, Mark Day, Julia L Rutkowski, Seth P Finklestein, Menelas N Pangalos, Michael Poole, Gary L Stiles, Robert R Ruffolo, Frank L Walsh
Affiliations
- PMID: 17579658
- DOI: 10.1038/sj.jcbfm.9600516
Review
Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke
Giora Z Feuerstein et al. J Cereb Blood Flow Metab. 2008 Jan.
Abstract
The continued failure in approving new drugs for treatment of acute stroke has been recently set back by the failure of the NXY-059 (Stroke-Acute Ischemic NXY Treatment (SAINT) II) trial. The disappointment was heightened by the latter study being viewed as a most promising compound for stroke drug development program based on the preclinical data. Since the SAINT I/II development program included many of the STAIR (Stroke Therapy Academic Industry Round table) guidelines, yet have still failed to achieve the expected efficacy, there is a clear need to continue and analyze the path forward for stroke drug discovery. To this end, this review calls for a consortium approach including academia, government (FDA/NIH), and pharmaceutical industry partnerships to define this path. It is also imperative that more attention is given to the evolving discipline of Translational Medicine. A key issue in this respect is the need to devote more attention to the characteristics of the drug candidate nature-target interaction, and its relationship to pharmacodynamic treatment end points. It is equally important that efforts are spent to prove that phenotypic outcomes are linked to the purported mechanism of action of the compound. Development of technologies that allows a better assessment of these parameters, especially in in vivo models are paramount. Finally, rational patient selection and new outcome scales tailored in an adaptive design model must be evaluated.
Similar articles
- Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials.
Savitz SI, Fisher M. Savitz SI, et al. Ann Neurol. 2007 May;61(5):396-402. doi: 10.1002/ana.21127. Ann Neurol. 2007. PMID: 17420989 Review. - NXY-059: review of neuroprotective potential for acute stroke.
Fong JJ, Rhoney DH. Fong JJ, et al. Ann Pharmacother. 2006 Mar;40(3):461-71. doi: 10.1345/aph.1E636. Epub 2006 Feb 28. Ann Pharmacother. 2006. PMID: 16507608 Review. - Therapeutic strategies for the treatment of stroke.
Green AR, Shuaib A. Green AR, et al. Drug Discov Today. 2006 Aug;11(15-16):681-93. doi: 10.1016/j.drudis.2006.06.001. Drug Discov Today. 2006. PMID: 16846795 Review. - Lessons learned from independent central review.
Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Ford R, et al. Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031. Eur J Cancer. 2009. PMID: 19101138
Cited by
- Stem cell therapy for cerebral ischemia: from basic science to clinical applications.
Abe K, Yamashita T, Takizawa S, Kuroda S, Kinouchi H, Kawahara N. Abe K, et al. J Cereb Blood Flow Metab. 2012 Jul;32(7):1317-31. doi: 10.1038/jcbfm.2011.187. Epub 2012 Jan 18. J Cereb Blood Flow Metab. 2012. PMID: 22252239 Free PMC article. Review. - Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective.
Di Napoli M, Shah IM. Di Napoli M, et al. J Aging Res. 2011;2011:857484. doi: 10.4061/2011/857484. Epub 2011 Oct 31. J Aging Res. 2011. PMID: 22132330 Free PMC article. - The neurovascular unit and combination treatment strategies for stroke.
Zhang L, Zhang ZG, Chopp M. Zhang L, et al. Trends Pharmacol Sci. 2012 Aug;33(8):415-22. doi: 10.1016/j.tips.2012.04.006. Epub 2012 May 16. Trends Pharmacol Sci. 2012. PMID: 22595494 Free PMC article. Review. - Long-term survival and serial assessment of stroke damage and recovery - practical and methodological considerations.
Modo M. Modo M. J Exp Stroke Transl Med. 2009 Jan;2(2):52-68. doi: 10.6030/1939-067X-2.2.52. J Exp Stroke Transl Med. 2009. PMID: 22389748 Free PMC article. - A comparative analysis of protein targets of withdrawn cardiovascular drugs in human and mouse.
Zhao Y, Wang J, Wang Y, Huang J. Zhao Y, et al. J Clin Bioinforma. 2012 May 1;2(1):10. doi: 10.1186/2043-9113-2-10. J Clin Bioinforma. 2012. PMID: 22548699 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources